AR042602A1 - Compuestos de 1,2,4-triazol - Google Patents

Compuestos de 1,2,4-triazol

Info

Publication number
AR042602A1
AR042602A1 ARP020104915A ARP020104915A AR042602A1 AR 042602 A1 AR042602 A1 AR 042602A1 AR P020104915 A ARP020104915 A AR P020104915A AR P020104915 A ARP020104915 A AR P020104915A AR 042602 A1 AR042602 A1 AR 042602A1
Authority
AR
Argentina
Prior art keywords
group
substituted
pyridyl
unsubstituted
cyano
Prior art date
Application number
ARP020104915A
Other languages
English (en)
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of AR042602A1 publication Critical patent/AR042602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un nuevo compuesto de 1,2,4-triazol es útil como agente terapéutico para la hiperuricemia y la gota provocada por hiperuricemia. Un compuesto se representa por la fórmula general (1). También se provee un proceso para la producción de un compuesto haciendo reaccionar un nitrilo y una hidracina, y un agente terapéutico, particularmente un inhibidor de xantina oxidasa. Reivindicación 1: Un compuesto de 1,2,4-triazol caracterizado porque se representa mediante la fórmula general (1), donde R2 representa un grupo piridilo no sustituido o un grupo piridilo sustituido con un grupo ciano, alquilo inferior, halógeno, alcoxi inferior o alquiltio inferior como sustituyente, R1 representa un grupo piridilo no sustituido o sustituido que puede estar sustituido con un halógeno, grupo ciano o fenilo como sustituyente, un grupo piridina-N-óxido correspondiente a dichos grupos piridilo, un grupo fenilo sustituido con un grupo ciano o nitro o un grupo fenilo sustituido con, además de un grupo ciano o nitro como sustituyente, un grupo alcoxi inferior sustituido o no sustituido, un grupo N-alquilo inferior-piperazino, un grupo alquiltio inferior, un grupo feniltio, o un grupo alquilamino inferior, siempre y cuando R1 no sea un grupo piridilo no sustituido, un grupo piridilo sustituido con un grupo alquilo inferior o un grupo piridina-N-óxido correspondiente a dichos grupos piridilo en el caso donde R2 sea un grupo piridilo no sustituido, o un grupo piridilo sustituido con un grupo inferior, y R3 representa hidrógeno o un grupo alquilo inferior sustituido con un grupo pivaloiloxi y en cada caso R3 se une a uno de lo átomos de nitrógeno en el anillo 1,2,4-triazol representado por la fórmula general (1), o un hidrato o una sal del mismo.
ARP020104915A 2002-01-28 2002-12-17 Compuestos de 1,2,4-triazol AR042602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002017825 2002-01-28

Publications (1)

Publication Number Publication Date
AR042602A1 true AR042602A1 (es) 2005-06-29

Family

ID=27653386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104915A AR042602A1 (es) 2002-01-28 2002-12-17 Compuestos de 1,2,4-triazol

Country Status (22)

Country Link
US (1) US7074816B2 (es)
EP (1) EP1471065B1 (es)
JP (1) JP3600832B2 (es)
CN (1) CN1561340B (es)
AR (1) AR042602A1 (es)
AT (1) ATE387438T1 (es)
AU (1) AU2002349754B2 (es)
BR (1) BRPI0212775B8 (es)
CA (1) CA2462132C (es)
DE (1) DE60225341T2 (es)
DK (1) DK1471065T3 (es)
ES (1) ES2300486T3 (es)
HK (1) HK1067132A1 (es)
MX (1) MXPA04004037A (es)
NO (1) NO326941B1 (es)
NZ (1) NZ531673A (es)
PL (1) PL208260B1 (es)
PT (1) PT1471065E (es)
RU (1) RU2293733C2 (es)
TW (1) TWI257926B (es)
WO (1) WO2003064410A1 (es)
ZA (1) ZA200401777B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060037373A (ko) * 2003-07-24 2006-05-03 가부시키가이샤 후지야쿠힝 1,2,4-트리아졸 화합물의 제조 방법 및 그 중간체
US20060189811A1 (en) * 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP1940397A4 (en) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A METHOD FOR TREATING HYPERTONIA
KR20080066938A (ko) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
KR20140037954A (ko) * 2006-06-22 2014-03-27 닛뽕 케미파 가부시키가이샤 항암제 내성 극복제
JP5110536B2 (ja) * 2006-07-19 2012-12-26 学校法人日本医科大学 筋萎縮性側索硬化症治療薬
KR20160031040A (ko) * 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
JP2010516691A (ja) * 2007-01-19 2010-05-20 タケダ ファーマシーティカルズ ノース アメリカ，アイエヌシー． 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
WO2012060308A1 (ja) * 2010-11-01 2012-05-10 株式会社 三和化学研究所 腎機能障害の予防又は治療に用いる医薬
RU2538964C1 (ru) 2010-12-17 2015-01-10 Мицубиси Танабе Фарма Корпорейшн Соединение с последовательной арициклической структурой, обладающее активностью ингибирования ацилкофермента а: диацилглицеринацилтрансферазы (dgat1)
WO2012118485A1 (en) 2011-03-01 2012-09-07 Empire Technology Development Llc Temperature controlled variable reflectivity coatings
RU2476428C1 (ru) * 2011-09-01 2013-02-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения дигидрохлорида 5-амино-3-аминометил-1,2,4-триазола
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
CN104411700B (zh) * 2012-07-25 2016-06-15 株式会社富士药品 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的多晶型及其制造方法
BR112014032229B1 (pt) * 2012-07-25 2021-02-09 Fujiyakuhin Co., Ltd. método para produzir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3- il]piridina-2-carbonitrila
CN103724329B (zh) * 2013-12-23 2015-02-18 济南百诺医药科技开发有限公司 4-[5-(吡啶-4-基)-1h-[1,2,4]三唑-3-基]吡啶-2-甲腈的制备方法
CN104042577B (zh) * 2014-06-13 2016-08-24 安徽省逸欣铭医药科技有限公司 一种稳定的托匹司他片及其制备方法
CN105315260A (zh) * 2014-07-29 2016-02-10 北京海步医药科技股份有限公司 一种托布司他一水合物晶型及其制备方法
CN105367490B (zh) * 2014-08-18 2019-01-04 上海医药工业研究院 合成托吡司他的新中间体及其制备方法
CN105348264B (zh) * 2014-08-18 2018-01-16 上海医药工业研究院 一种托吡司他的合成方法
CN104151297B (zh) * 2014-08-27 2016-03-16 王庆本 4-[5-(吡啶-4-基)-1h-[1，2，4]三唑-3-基]吡啶-2-甲腈的制备方法
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬
JP6891108B2 (ja) 2015-02-24 2021-06-18 国立大学法人鳥取大学 認知症の予防及び／又は治療のための医薬
CN107531677A (zh) * 2015-02-25 2018-01-02 法尔玛赞公司 用于制备托匹司他及其中间体的方法
CN105693699B (zh) * 2015-03-30 2019-06-18 苏州晶云药物科技股份有限公司 托吡司他的晶型及其制备方法
CN104910068B (zh) * 2015-04-24 2017-07-14 南京医科大学 一种2‑氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
CN106279111A (zh) * 2015-05-12 2017-01-04 北京济美堂医药研究有限公司 一种精制托吡司他的新方法
CN104961730B (zh) * 2015-06-18 2017-05-17 山东金城医药化工股份有限公司 托吡司他新晶型及其制备方法
CN105130958B (zh) * 2015-08-31 2017-10-31 济南康和医药科技有限公司 5‑(2‑氰基4‑吡啶基)‑3‑(4‑吡啶基)‑1,2,4‑三唑的制备工艺
CN105294656A (zh) * 2015-10-10 2016-02-03 大道隆达（北京）医药科技发展有限公司 一种托匹司他的制备工艺和方法
CN106336399A (zh) * 2015-11-03 2017-01-18 江苏悦兴药业有限公司 托匹司他工艺杂质的制备方法
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
CN105399732A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种托匹司他的制备方法
CN106008465A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 一种托匹司他杂质的合成方法
CN108250183A (zh) * 2016-12-29 2018-07-06 北京诚济制药有限公司 一种高纯度的托匹司他的制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN107652271B (zh) * 2017-11-06 2020-06-16 上海中拓医药科技有限公司 一种托匹司他晶型i的制备方法
CN108017619B (zh) * 2017-12-06 2020-08-11 成都惟邦药业有限公司 一种托匹司他杂质及其制备方法
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN113666909B (zh) * 2020-05-14 2024-07-02 鲁南制药集团股份有限公司 一种托匹司他的制备方法
CN114773262B (zh) * 2022-05-19 2024-05-07 兄弟科技股份有限公司 2-氰基-4-吡啶羧酸甲酯的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (es) * 1970-09-25 1972-03-28
US3947577A (en) * 1973-05-21 1976-03-30 Merck & Co., Inc. Anti-hyperuricemia composition
US3963731A (en) * 1973-05-21 1976-06-15 Merck & Co., Inc. Pyridyl containing 1-benzenesulfonyl triazoles
US3928361A (en) * 1973-05-21 1975-12-23 Merck & Co Inc 1-(Sulfamoylphenylalkyl)-3,5-dipyridyl-1,2,4 triazoles
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
US3882134A (en) * 1973-05-21 1975-05-06 Merck & Co Inc 1-Substituted-3,5-dipyridyl-1,2,4-triazoles
US4104393A (en) * 1976-04-02 1978-08-01 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
ES2133312T3 (es) * 1991-12-05 1999-09-16 Wallac Oy Quelatos de lantanidos luminiscentes.
WO2000024735A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
EP1379525B1 (en) * 2001-02-21 2007-10-10 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
CA2462132A1 (en) 2003-08-07
DE60225341D1 (de) 2008-04-10
JP3600832B2 (ja) 2004-12-15
WO2003064410A1 (fr) 2003-08-07
HK1067132A1 (es) 2005-04-01
TW200302222A (en) 2003-08-01
PL208260B1 (pl) 2011-04-29
EP1471065A4 (en) 2005-06-15
ZA200401777B (en) 2005-08-31
NZ531673A (en) 2006-06-30
AU2002349754B2 (en) 2008-01-31
DE60225341T2 (de) 2009-04-09
BR0212775A (pt) 2004-10-13
DK1471065T3 (da) 2008-03-25
RU2004106554A (ru) 2005-07-27
PL368672A1 (en) 2005-04-04
BRPI0212775B1 (pt) 2017-06-06
NO20041075L (no) 2004-03-15
US7074816B2 (en) 2006-07-11
EP1471065A1 (en) 2004-10-27
BRPI0212775B8 (pt) 2021-05-25
NO326941B1 (no) 2009-03-16
PT1471065E (pt) 2008-03-13
ES2300486T3 (es) 2008-06-16
CA2462132C (en) 2010-08-10
US20050004175A1 (en) 2005-01-06
TWI257926B (en) 2006-07-11
MXPA04004037A (es) 2004-07-23
RU2293733C2 (ru) 2007-02-20
CN1561340B (zh) 2012-05-23
ATE387438T1 (de) 2008-03-15
JPWO2003064410A1 (ja) 2005-05-26
EP1471065B1 (en) 2008-02-27
CN1561340A (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
AR042602A1 (es) Compuestos de 1,2,4-triazol
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
ATE461179T1 (de) Hemmer der akt aktivität
ATE503483T1 (de) Hemmer der akt aktivität
EA200500017A1 (ru) Новые соединения
AU2003264060A8 (en) Phenacyl xanthine derivatives as dpp-iv inhibitor
DE60225709D1 (de) Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
PE20020469A1 (es) Policiclicos nucleotidicos como inhibidores de xantina fosfodiesterasa v
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
NI200800008A (es) Métodos para la neuroprotección
AR061492A2 (es) Procedimiento para la preparacion de compuestos intermediarios para la preparacion de 5-amino-1-aril-3-ciano pirazoles
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
PL1757610T3 (pl) Skondensowana pochodna pirymidyny oraz inhibitor oksydazy ksantynowej
NO20064175L (no) Heterosyklisk forbindelse
CO6190578A2 (es) Novedosos derivados de imidazol
WO2008036967A3 (en) Novel heterocyclic compounds as lasy activators
ECSP066983A (es) Un método fácil para sintetizar compuestos de bacatina iii
AR002829A1 (es) Procedimiento para preparar compuestos de 3-hidroxipirazol n-sustituidos.
EA200801123A1 (ru) Производные 6-гетероарилпиридоиндолона, способ их получения и применение их в терапии
ATE446295T1 (de) 2-amino-4-pyridylmethyl-thiazolinderivate und ihre verwendung als induzierbare no-synthase inhibitoren
DK1325923T3 (da) Cephem-forbindelser og ESBL-detekterende reagenser indeholdende disse
MX2007001952A (es) Compuestos y composiciones utiles como inhibidores de catepsina-s.

Legal Events

Date Code Title Description
FC Refusal